As a result, combining EGFR-TKIs with immune checkpoint inhibitors, such as PD-1/PD-L1 inhibitors, holds potential for remodeling the immune microenvironment and strengthening the anti-tumor immune response. This evidence concerns the gene CD274 and neoplasm.